

PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD		
CODE/NAME & ADDRESS : C000138355	(MEDIWHEEL) ACCESSION NO : 0290WD005366 AGE/SEX :47 Years Male		
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST			
DELHI NEW DELHI 110020	RECEIVED : 22/04/2023 11:28:13 REPORTED : 24/04/2023 16:42:27		
NEW DELHI 110030 8800465156			
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units	
MEDI WHEEL FULL BODY HEALTH CHECK UP ABO	DVE 40 MALE		
»»	BOTH THE LUNG FIELDS ARE CLEAF		
»»	BOTH THE COSTOPHRENIC AND CA		
»»	BOTH THE HILA ARE NORMAL		
»»	CARDIAC AND AORTIC SHADOWS APPEAR NORMAL		
»»	BOTH THE DOMES OF THE DIAPHRA	M ARE NORMAL	
»»	VISUALIZED BONY THORAX IS NORMAL		
IMPRESSION	NO ABNORMALITY DETECTED		
	Dr G.S. Saluja, (MBBS,DMRD) (Consultant Radiologist)		
TMT OR ECHO			
TMT OR ECHO	NEGATIVE		
ECG			
ECG	SINUS RHYTHM.		
	LEFTWARD AXIS.		
	INCOMPETE RIGHT BUNDLE BRANC	H BLOCK.	
	OTHERWEISE NORMAL ECG.		
MEDICAL HISTORY			
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT		
RELEVANT PAST HISTORY	HTN 10- YEARS		
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT		
RELEVANT FAMILY HISTORY	PARENTS :- HTN/DM		
OCCUPATIONAL HISTORY	NOT SIGNIFICANT		
HISTORY OF MEDICATIONS	NOT SIGNIFICANT		
ANTHROPOMETRIC DATA & BMI	4 70		
HEIGHT IN METERS	1.79	mts	
WEIGHT IN KGS.	79	Kgs	



Dr.Arpita Pasari, MD Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008



View Report







PATIENT NAME : ASHISH SHRIVASTAVA	REF	. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290WD	AGE/SEX :47 Years Male
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : ASHIM260	276290 DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	SHENT BATIENT ID:	RECEIVED : 22/04/2023 11:28:13
NEW DELHI 110030		REPORTED :24/04/2023 16:42:27
8800465156		
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
BMI	25	BMI & Weight Status as followg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT	
BUILT / SKELETAL FRAMEWORK	AVERAGE	
FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDI	ĒR
THYROID GLAND	NOT ENLARGED	
CAROTID PULSATION	NORMAL	
TEMPERATURE	AFEBRILE	
PULSE	BRUIT	ERIPHERAL PULSES WELL FELT, NO CAROTID
RESPIRATORY RATE	NORMAL	
CARDIOVASCULAR SYSTEM		
BP	130/80 MM HG (SUPINE)	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	



Dr.Arpita Pasari, MD **Consultant Pathologist**

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel: 0731 2490008



š 🗖

3







PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR :	DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355	ACCESSION NO : 0290WD005366	AGE/SEX :47 Years Male
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	PATIENT ID : ASHIM260276290	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	SETENT BATTENT ID:	RECEIVED : 22/04/2023 11:28:13
NEW DELHI 110030		REPORTED :24/04/2023 16:42:27
8800465156		
Test Report Status <u>Final</u>	Results Biologica	al Reference Interval Units
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
PER ABDOMEN		
APPEARANCE	NORMAL	
VENOUS PROMINENCE	ABSENT	
LIVER	NOT PALPABLE	
SPLEEN	NOT PALPABLE	
HERNIA	ABSENT	
CENTRAL NERVOUS SYSTEM		
HIGHER FUNCTIONS	NORMAL	
CRANIAL NERVES	NORMAL	
CEREBELLAR FUNCTIONS	NORMAL	
SENSORY SYSTEM	NORMAL	
MOTOR SYSTEM	NORMAL	
REFLEXES	NORMAL	
MUSCULOSKELETAL SYSTEM		
SPINE	NORMAL	
JOINTS	NORMAL	
BASIC EYE EXAMINATION		
CONJUNCTIVA	NORMAL	
EYELIDS	NORMAL	
EYE MOVEMENTS	NORMAL	
CORNEA	NORMAL	
DISTANT VISION RIGHT EYE WITH GLASSES	6/6, WITH GLASSES NORMAL	
DISTANT VISION LEFT EYE WITH GLASSES	6/6, WITH GLASSES NORMAL	
NEAR VISION RIGHT EYE WITH GLASSES	N10, VISUAL ACUITY FOR CORRECTIO	N
NEAR VISION LEFT EYE WITH GLASSES	N12, VISUAL ACUITY FOR CORRECTIO	Ν
COLOUR VISION	NORMAL	
BASIC ENT EXAMINATION		
EXTERNAL EAR CANAL	NORMAL	
TYMPANIC MEMBRANE	NORMAL	
NOSE	NO ABNORMALITY DETECTED	

Apita

Dr.Arpita Pasari, MD **Consultant Pathologist**



۶D

3



View Details





PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR : [(DR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0290WD005366 PATIENT ID : ASHIM260276290 GLIENT BATIENT ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

SINUSES	NORMAL
THROAT	NORMAL
TONSILS	NOT ENLARGED
SUMMARY	
RELEVANT HISTORY	NOT SIGNIFICANT
RELEVANT GP EXAMINATION FINDINGS	OVERWEIGHT
REMARKS / RECOMMENDATIONS	NONE
FITNESS STATUS	
FITNESS STATUS	FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)
Comments	
CLINICAL FINDINGS:-	
RAISED FBA AND PPBS.	
RAISED ESTIMATED AVERAG GLUCOSE (EAG)	
RAISED SGPT.	

DYSLIPIDEMIA.

USG SHOWS EARLY FATTY INFILTRATION OF LIVER.

OVER WEIGHT STATUS.

FITNESS STATUS :-

FITNESS STATUS : FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

ADVICE: WEIGHT REDUCTION, LOW FAT& CARBOHYDRATE DIET AND REGULAR PHYSICAL EXERCISE FOR OVERWEIGHT STATUS AND DYSLIPIDEMIA.

NEED PHYSICIAN CONSULTATION FOR LIFE STYLE MODIFICATION.

B

Dr.Arpita Pasari, MD Consultant Pathologist

Page 4 Of 20

View Report



View Details





Units

PATIENT NAME : ASHISH SHRIVASTAVA		OR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WD005366 PATIENT ID : ASHIM260276290 GHENT PATIENT ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27

Results

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ULTRASOUND ABDOMEN **ULTRASOUND ABDOMEN**

Final

DONE

Comments

Test Report Status

USG

IMPRESSION- EARLY FATTY INFILTRATION OF LIVER.

Interpretation(s) MEDICAL

HISTORY-** THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for . These are then further correlated with details of the job under consideration to eventually fit the right man to the right job. Basis the above, SRL classifies a candidate's Fitness Status into one of the following categories:

• Fit (As per requested panel of tests) - SRL Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.

• Fit (with medical advice) (As per requested panel of tests) - This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician''''s

consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job. • Fitness on Hold (Temporary Unfit) (As per requested panel of tests) - Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc.

• Unfit (As per requested panel of tests) - An unfit report by SRL Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.



Dr.Arpita Pasari, MD **Consultant Pathologist**

Page 5 Of 20





View Report

View Details



Test Report Status

Final



Biological Reference Interval Units

PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR :	DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WD005366 PATIENT ID : ASHIM260276290 SHEAN BATIENT ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED : 22/04/2023 11:28:13 REPORTED : 24/04/2023 16:42:27

Results

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP A	BOVE 40 MALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : SPECTROPHOTOMETRY	13.9	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	4.70	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : ELECTRICAL IMPEDANCE	5.40	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : ELECTRICAL IMPEDANCE	182	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED	42.0	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED	89.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	29.6	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	33.1	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED	11.9	11.6 - 14.0	%
MENTZER INDEX	18.9		
MEAN PLATELET VOLUME (MPV) METHOD : CALCULATED	10.4	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : IMPEDANCE / MICROSCOPY	63	40 - 80	%
LYMPHOCYTES METHOD : IMPEDANCE / MICROSCOPY	30	20 - 40	%
MONOCYTES METHOD : IMPEDANCE / MICROSCOPY	05	2 - 10	%
EOSINOPHILS	02	1 - 6	%



Dr.Arpita Pasari, MD Consultant Pathologist



Page 6 Of 20



View Details View Report



PATIENT NAME : ASHISH SHRIVASTAVA	RI	EF. DOCTOR : D (R. ACROFE MEDIWHEE		e ltd
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290W РАПЕNT ID : ASHIM2 SHFAN BATIENT ID:	60276290	DRAWN RECEIVED	:47 Years : :22/04/2023 :24/04/2023	
Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval l	Jnits
METHOD : IMPEDANCE / MICROSCOPY BASOPHILS METHOD : IMPEDANCE / MICROSCOPY	00	0 - 2		%	
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED	3.40	2.0 - 7.0		tho	οu/μL
ABSOLUTE LYMPHOCYTE COUNT	1.62	1.0 - 3.0		tho	οu/μL

METHOD : CALCULATED			
ABSOLUTE MONOCYTE COUNT	0.27	0.2 - 1.0	thou/µL
METHOD : CALCULATED			
ABSOLUTE EOSINOPHIL COUNT	0.11	0.02 - 0.50	thou/µL
METHOD : CALCULATED			

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

MBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.



Dr.Arpita Pasari, MD **Consultant Pathologist**

Page 7 Of 20



Vie<u>w Details</u>





Biological Reference Interval Units

PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR	: DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WD005366 PATIENT ID : ASHIM260276290 GEIENT PATIENT ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27

	HAEMATOLOG	(
MEDI WHEEL FULL BODY HEAL	TH CHECK UP ABOVE 40 MALE		
ERYTHROCYTE SEDIMENTATIO	N RATE (ESR),WHOLE		
F.S.R	13	0 - 14	mm at 1 hr

Results

Interpretation(s)

Test Report Status

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Final

EXTINCOUTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammator condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnance while the sector and the sector in a sector in sector and the sector in the sector is t

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.



Dr.Arpita Pasari, MD **Consultant Pathologist**







View Report

View Details





Biological Reference Interval Units

PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR	: DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WD005366 PATIENT ID : ASHIM260276290 ABIENT BATIENT ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27

Results

	IMMUNOHAEMATOLOGY	
MEDI WHEEL FULL BODY HEALTH C	IECK UP ABOVE 40 MALE	
ABO GROUP & RH TYPE, EDTA WHO	LE BLOOD	
ABO GROUP METHOD : TUBE AGGLUTINATION	TYPE B	
RH TYPE METHOD : TUBE AGGLUTINATION	POSITIVE	

Test Report Status

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Final



Dr.Arpita Pasari, MD **Consultant Pathologist**



Page 9 Of 20

View Report

View Details



Test Report Status

Final



Biological Reference Interval Units

PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WD005366 РАПЕНТ ID : ASHIM260276290 ЄНТАЛВАПЕНТ ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27	

Results

			······
	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECK UP	ABOVE 40 MALE		
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT	A WHOLE		
BLOOD		N	0/
HBA1C	5.7	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
	116.9 High	< 116.0	mg/dL
ESTIMATED AVERAGE GLUCOSE(EAG)	110.7 IIIYII	< 110.0	iiig/uL
	106 18-6	74 00	ma/dl
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	106 High	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR)	168 High	Normal: < 140, Impaired Glucose Tolerance:140-199 Diabetic > or = 200	mg/dL
METHOD : HEXOKINASE			
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	220 High	Desirable: <200 BorderlineHigh : 200-239 High : > or = 240	mg/dL
METHOD : OXIDASE, ESTERASE, PEROXIDASE			<i>(</i>))
TRIGLYCERIDES	232 High	Desirable: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High : > or = 500	mg/dL
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL	37 Low	< 40 Low > or = 60 High	mg/dL
METHOD : DIRECT- NON IMMUNOLOGICAL			

Appita

Dr.Arpita Pasari, MD Consultant Pathologist



Page 10 Of 20







PATIENT NAME : ASHISH SHRIVASTAVA		REF. DOCTOR : DR. ACROFEMI HEALTHCARE (MEDIWHEEL)	LTD
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 029 PATIENT ID : ASH SHENNBATIENT ID:	OWD005366 AGE/SEX :47 Years IM260276290 DRAWN : RECEIVED :22/04/2023 1 REPORTED :24/04/2023 1	
Test Report Status <u>Final</u>	Results	Biological Reference Interval Ur	nits
CHOLESTEROL LDL	137 High	Adult levels: mg/c Optimal < 100 Near optimal/above optimal: 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	dL
NON HDL CHOLESTEROL	183 High	Desirable: Less than 130 mg/o Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	dL
METHOD : CALCULATED			
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED	46.4 High	< or = 30 mg/c	dL
CHOL/HDL RATIO	6.0 High	3.3 - 4.4	
LDL/HDL RATIO	3.7 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non

Dr.Arpita Pasari, MD Consultant Pathologist

Page 11 Of 20



View Details View Report





PATIENT NAME : ASHISH SHRIVASTAVA		DR. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WD005366 РАПЕНТ ID : ASHIM260276290 Сыңаталар	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk	group or recurrent ACS (within 1 year) despite LDL-C	
	< or $=$ 50 mg/dl or polyvascular disease		
Very High Risk		major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk		abetes with 1 major risk factor or no evidence of end	
		DL >190 mg/dl 5. Extreme of a single risk factor. 6.	
	Coronary Artery Calcium - CAC >300 AU.	7. Lipoprotein a $>= 50 \text{mg/dl}$ 8. Non stenotic carotid	
	plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors		
1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females		3. Current Cigarette smoking or tobacco use	
2. Family history of p	remature ASCVD	4. High blood pressure	
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.48	0.0 - 1.2	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.17	0.0 - 0.2	mg/dL
METHOD : DIAZOTIZATION			

Dr.Arpita Pasari, MD **Consultant Pathologist**

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel: 0731 2490008



View Report



Details





PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WDO PATIENT ID : ASHIM260 SEIENT BATIENT ID:	276290 DR. REG	E/SEX :47 Years Male AWN : CEIVED :22/04/2023 11:28:13 PORTED :24/04/2023 16:42:27
Test Report Status <u>Final</u>	Results	Biological Ref	erence Interval Units
BILIRUBIN, INDIRECT METHOD : CALCULATED	0.31	0.00 - 1.00	mg/dL
TOTAL PROTEIN METHOD : BIURET	8.0	6.4 - 8.3	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	5.1	3.50 - 5.20	g/dL
GLOBULIN METHOD : CALCULATED	2.9	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED	1.8	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : UV WITH P5P	17	UPTO 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : UV WITH P5P	46 High	UP TO 45	U/L
ALKALINE PHOSPHATASE METHOD : PNPP	112	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE	24	8 - 61	U/L
LACTATE DEHYDROGENASE METHOD : ENZYMATIC LACTATE - PYRUVATE(IFCC) BLOOD UREA NITROGEN (BUN), SERUM	177	135 - 225	U/L
BLOOD UREA NITROGEN METHOD : UREASE KINETIC	9	6 - 20	mg/dL
CREATININE, SERUM CREATININE METHOD : ALKALINE PICRATE KINETIC JAFFES	0.87	0.70 - 1.20	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD : CALCULATED	10.34	5.0 - 15.0	
URIC ACID, SERUM URIC ACID METHOD : URICASE/CATALASE UV	7.7 High	3.5 - 7.2	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD : BIURET	8.0	6.4 - 8.3	g/dL

Apita

Dr.Arpita Pasari, MD Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008





View Details View Report





PATIENT NAME : ASHISH SH	RIVASTAVA	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)			
CODE/NAME & ADDRESS : C000138355 ACCES		ACCESSION NO :	0290WD005366	AGE/SEX :47 Years	Male
ACROFEMI HEALTHCARE LTD (M	,	PATIENT ID :	ASHIM260276290	DRAWN :	
F-703, LADO SARAI, MEHRAULI	SOUTH WEST	CHIENT BATIENT ID):	RECEIVED : 22/04/20)23 11:28:13
DELHI NEW DELHI 110030		ABHA NO :		REPORTED :24/04/20	
8800465156					
Test Report Status Final		Results	Biologica	Reference Interval	Units
ALBUMIN, SERUM					
ALBUMIN		5.1	3.5 - 5.2		g/dL
METHOD : BROMOCRESOL GREEN					-
GLOBULIN					
GLOBULIN		2.9	2.0 - 4.1		g/dL
ELECTROLYTES (NA/K/CL), S	ERUM				
SODIUM, SERUM		144.9	136- 145		mmol/L
POTASSIUM, SERUM		3.85	3.50- 5.1	0	mmol/L
CHLORIDE, SERUM		103.0	98 - 107		mmol/L
Interpretation(s)					
Sodium	Potassium		Chloride		
Decreased in:CCF, cirrhosis,	Decreased in: Lo		Decreased in: Vomiting,		
vomiting, diarrhea, excessive sweating, salt-losing	RTA types I and I	ed vomiting or diarrhea, renal failure combined with salt d II, deprivation, over-treatment with			
nephropathy, adrenal insufficiency,	hyperaldosteron				
nephrotic syndrome, water	syndrome,osmot	tic diuresis (e.g., diabetic ketoacidosis, excessive			

nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide,carbamazepine,anti depressants (SSRI), antipsychotics.	syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA,dehydration, overtreatment with saline,hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis,hyperadrenocorticism. Drugs: acetazolamide,androgens, hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s) GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.
 Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).



Dr.Arpita Pasari, MD **Consultant Pathologist**

Page 14 Of 20





Patient Ref. No. 775000002982331







Biological Reference Interval Units

PATIENT NAME : ASHISH SHRIVASTAVA		R. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)	ΠΕΝΤΙΟ : ASHIM260276290	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

Results

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

Final

HbA1c Estimation can get affected due to :

Test Report Status

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is GLUCOSE FASTING, FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. **Decreased in**:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide, and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin wher there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis.obstruction of bile ducts.cirrhosis

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

Dr.Arpita Pasari, MD Consultant Pathologist



Page 15 Of 20

View Report

View Details

Patient Ref. No. 775000002982331



PATIENT NAME : ASHISH SHRIVASTAVA REF. DOCTOR : DR. ACROFEMI HEALTHCARE (MEDIWHEEL)		
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0290WD005366 PATIENT ID : ASHIM260276290 SHIAN BATIENT ID:	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

CREATININE, SERUM-Higher than normal level may be due to:

CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as sbrakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome.Protein-losing enteropathy etc.

syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.



Dr.Arpita Pasari, MD **Consultant Pathologist**







View Report

<u>View Details</u>





PATIENT NAME : ASHISH SHRIVASTAVA	REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL)		
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST	РАПЕНТ ID : ASHIM260276290	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27	

Test F	Report	Status	<u>Final</u>
--------	--------	--------	--------------

Results

Biological Reference Interval Units

CLINICAL PATH - URINALYSIS				
MEDI WHEEL FULL BODY HEALTH CHECK U	P ABOVE 40 MALE			
PHYSICAL EXAMINATION, URINE				
COLOR	PALE YELLOW			
APPEARANCE	CLEAR			
CHEMICAL EXAMINATION, URINE				
РΗ	7.5	4.7 - 7.5		
SPECIFIC GRAVITY	1.010	1.003 - 1.035		
PROTEIN	NOT DETECTED	NOT DETECTED		
GLUCOSE	NOT DETECTED	NOT DETECTED		
KETONES	NOT DETECTED	NOT DETECTED		
BLOOD	NOT DETECTED	NOT DETECTED		
BILIRUBIN	NOT DETECTED	NOT DETECTED		
JROBILINOGEN	NORMAL	NORMAL		
NITRITE	NOT DETECTED	NOT DETECTED		
_EUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED		
MICROSCOPIC EXAMINATION, URINE				
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF	
PUS CELL (WBC'S)	2-3	0-5	/HPF	
EPITHELIAL CELLS	2-3	0-5	/HPF	
CASTS	NOT DETECTED			
CRYSTALS	NOT DETECTED			
BACTERIA	NOT DETECTED	NOT DETECTED		
(EAST	NOT DETECTED	NOT DETECTED		
REMARKS	Please note that all the urinary findings are confirmed manually as well.			

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	

B

Dr.Arpita Pasari, MD Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd (Formerly SRL Ltd) Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India Tel : 0731 2490008 Page 17 Of 20

View Report







PATIENT NAME : ASHISH SHRIVASTAVA REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD (MEDIWHEEL) CODE/NAME & ADDRESS : C000138355 ACCESSION NO : 0290WD005366 AGE/SEX :47 Years Male ACROFEMI HEALTHCARE LTD (MEDIWHEEL) : ASHIM260276290 PATIENT ID DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST ALLENT BATTENT ID: RECEIVED : 22/04/2023 11:28:13 DELHI REPORTED :24/04/2023 16:42:27 NEW DELHI 110030 8800465156

Test Report Status	<u>Final</u>
--------------------	--------------

Results

Biological Reference Interval Units

Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Apita

Dr.Arpita Pasari, MD **Consultant Pathologist**





View Details





PATIENT NAME : ASHISH SHRIVASTAVA		R. ACROFEMI HEALTHCARE LTD MEDIWHEEL)
CODE/NAME & ADDRESS : C000138355 ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	PATIENT ID : ASHIM260276290	AGE/SEX :47 Years Male DRAWN : RECEIVED :22/04/2023 11:28:13 REPORTED :24/04/2023 16:42:27

Test Report Status	<u>Final</u>
--------------------	--------------

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE				
MEDI WHEEL FULL BODY HEALTH CHECK U	IP ABOVE 40 MALE			
THYROID PANEL, SERUM				
ТЗ	125.00	80.0 - 200.0	ng/dL	
METHOD : CHEMILUMINESCENCE TECHNOLOGY				
T4	8.37	5.10 - 14.10	µg/dL	
METHOD : CHEMILUMINESCENCE TECHNOLOGY				
TSH (ULTRASENSITIVE)	3.240	0.270 - 4.200	µIU/mL	
METHOD : CHEMILUMINESCENCE TECHNOLOGY				
Interpretation(s)				

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor

Dr.Arpita Pasari, MD Consultant Pathologist



Page 19 Of 20

View Report

View Details





REF. DOCTOR : DR. ACROFEMI HEALTHCARE LTD **PATIENT NAME : ASHISH SHRIVASTAVA** (MEDIWHEEL) CODE/NAME & ADDRESS : C000138355 ACCESSION NO : 0290WD005366 AGE/SEX :47 Years Male ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : ASHIM260276290 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST RECEIVED : 22/04/2023 11:28:13 GETENT BATIENT ID: DELHI REPORTED :24/04/2023 16:42:27 **NEW DELHI 110030** 8800465156

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism	
8 N	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9 L	Low	High	High	Normal	rmal (1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.

2. All tests are performed and reported as per the

turnaround time stated in the AGILUS Directory of Services. 3. Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

 AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
 Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be

interpreted by registered medical practitioners only to determine final diagnosis. 7. Test results may vary based on time of collection.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

Test results cannot be used for Medico legal purposes.
 In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr.Arpita Pasari, MD Consultant Pathologist

Page 20 Of 20

View Report



View Details

